The effect of participatory action research on HPV primary preventive measures among in-school adolescents in Benue State, Nigeria.

Publisher: BioMed Central Country of Publication: England NLM ID: 100968562 Publication Model: Electronic Cited Medium: Internet ISSN: 1471-2458 (Electronic) Linking ISSN: 14712458 NLM ISO Abbreviation: BMC Public Health Subsets: MEDLINE

Original Publication: London : BioMed Central, [2001-

Papillomavirus Infections*/prevention & control ; Health Knowledge, Attitudes, Practice*; Humans ; Nigeria ; Adolescent ; Female ; Male ; Cross-Sectional Studies ; Young Adult ; Child ; Papillomavirus Vaccines/administration & dosage ; Community-Based Participatory Research ; Primary Prevention/methods ; Schools ; School Health Services ; Surveys and Questionnaires ; Health Services Research

Background: Individuals with a higher level of awareness and knowledge of HPV are more likely to dispel misconceptions about HPV and reduce their likelihood of engaging in risky sexual behavior. Behavioural change can be achieved through interventions such as participatory action research (PAR), which has been applied in various contexts. Few studies have reported on the use of PAR in Nigeria. This study aims to utilise PAR as an intervention to increase HPV awareness, improve knowledge of HPV infection, and promote behavioural change for HPV prevention among young adolescents in Benue State, Nigeria.
Methods: The study design uses a school-based, pre-post intervention approach with a cross-sectional component. Study participants are young adolescents aged 10-19 years in selected co-educational secondary schools in three local government areas (LGAs) spread across the three senatorial zones in Benue State, Nigeria. Two-stage sampling was used to select the LGAs and schools, and the sample size was computed using the before and after implementation with some prior information from a previous study. Data on sociodemographic characteristics, HPV awareness and knowledge of infection and prevention, prevention practices, and willingness for HPV vaccination were obtained with a self-administered semi-structured questionnaire adapted from the Vaccination and HPV Knowledge (THinK) survey. The HPV Knowledge survey (New Zealand) was utilized to collect information from students at baseline and post-implementation after PAR intervention. The Wilcoxon Signed Test (WST) was used to investigate the significance of the median differences before and after the intervention. A p-value less than 0.05 or 0.001 was considered significant.
Results: A total of 548 adolescents were sampled before the intervention. After the intervention, the sample size decreased to 503, reflecting an 8% attrition rate. PAR effectively increased HPV awareness among the participants from 80.9% before the intervention to 99.8% afterward. The PAR led to a significant change in knowledge of HPV infection and primary prevention and an increase in perception of HPV primary prevention. decrease in misconceptions and risky sexual behaviours, increase in HIV screening tests, and increase in the willingness of participants to uptake the HPV vaccine. Among the measures of risky sexual behaviours was a decreased perception that having more than one sexual partner is not a risk factor for HPV after the PAR intervention. The number of participants in sexual relationships decreased from 84 (16.7%) at baseline to 37 (7.4%) post-implementation. The PAR also led to a decrease in the number of participants who reported having STDs. The Wilcoxon Signed test was further disaggregated based on sex (male and female), school funding type (public and private), and school class level (junior and senior).
Conclusions: PAR led to a significant increase in awareness and knowledge of HPV, knowledge of different aspects of HPV infection, and willingness to uptake the HPV vaccine. Additionally, the study has provided evidence that PAR interventions can be a viable tool in delaying sexual initiation and reducing sexual behavioural tendencies, especially in high-risk groups.
(© 2024. The Author(s).)

Viruses. 2021 Aug 19;13(8):. (PMID: 34452508)
PLoS One. 2020 Apr 10;15(4):e0230242. (PMID: 32275669)
Reprod Health. 2020 Jun 11;17(1):94. (PMID: 32527331)
BMC Public Health. 2021 Jul 21;21(1):1439. (PMID: 34289834)
BMC Public Health. 2023 May 26;23(1):974. (PMID: 37237329)
Front Glob Womens Health. 2021 Jul 19;2:697607. (PMID: 34816234)
Biochem Med (Zagreb). 2021 Feb 15;31(1):010502. (PMID: 33380887)
Health Promot Pract. 2022 Jan;23(1):25-31. (PMID: 33858267)
Health Res Policy Syst. 2021 Aug 11;19(Suppl 2):88. (PMID: 34380510)
J Med Internet Res. 2020 Jul 31;22(7):e15378. (PMID: 32735217)
Prev Med. 2016 Dec;93:147-150. (PMID: 27713099)
Int J Qual Methods. 2020 Jan-Feb;19:. (PMID: 34764823)
BMC Womens Health. 2021 Dec 18;21(1):419. (PMID: 34922503)
PLoS One. 2022 Mar 22;17(3):e0264304. (PMID: 35316275)
J Clin Nurs. 2018 Apr;27(7-8):e1600-e1611. (PMID: 29495076)
J Behav Med. 2024 Apr;47(2):334-341. (PMID: 38180576)
PeerJ. 2019 May 09;7:e6254. (PMID: 31119063)
Pan Afr Med J. 2019 Mar 18;32:130. (PMID: 31223418)
PLoS One. 2018 Dec 31;13(12):e0197648. (PMID: 30596646)
Nat Rev Dis Primers. 2019 Nov 21;5(1):79. (PMID: 31754194)
Int J Environ Res Public Health. 2023 Mar 09;20(6):. (PMID: 36981767)
Health Educ Behav. 2023 Feb;50(1):107-120. (PMID: 33870765)
Vaccines (Basel). 2021 Jan 19;9(1):. (PMID: 33477779)
Glob Health Action. 2020;13(1):1726722. (PMID: 32116156)
PLoS One. 2020 Mar 5;15(3):e0230046. (PMID: 32134985)
Exp Ther Med. 2020 Dec;20(6):186. (PMID: 33101476)
BMC Public Health. 2021 Dec 30;21(1):2327. (PMID: 34969391)
Pan Afr Med J. 2021 May 21;39:62. (PMID: 34422185)
J R Soc Med. 2020 Feb;113(2):64-78. (PMID: 31962050)
J Obstet Gynaecol. 2020 Jul;40(5):602-608. (PMID: 31500479)
BMC Public Health. 2024 Aug 8;24(1):2154. (PMID: 39118089)
BMC Public Health. 2022 Aug 24;22(1):1611. (PMID: 36002832)
J West Afr Coll Surg. 2024 Apr-Jun;14(2):146-153. (PMID: 38562384)
Gynecol Oncol. 2020 Feb;156(2):498-502. (PMID: 31848025)
J Cancer Educ. 2020 Oct;35(5):850-859. (PMID: 31925677)
PLoS One. 2022 Mar 30;17(3):e0265269. (PMID: 35353833)
PLoS One. 2023 Jan 18;18(1):e0279077. (PMID: 36652442)
Ther Adv Infect Dis. 2023 Feb 18;10:20499361231153549. (PMID: 36814516)
Vaccine. 2022 Sep 2;40(37):5413-5432. (PMID: 35965239)
Front Public Health. 2022 Jul 08;10:890880. (PMID: 35875040)
Reprod Health. 2021 Oct 10;18(1):201. (PMID: 34629088)

Keywords: Behaviour; HIV; HPV; Nigeria; Participatory action research; Wilcoxon signed test

0 (Papillomavirus Vaccines)

Date Created: 20241102 Date Completed: 20241102 Latest Revision: 20241105

20241105

PMC11529337

10.1186/s12889-024-20536-3

39487403